Annual Drug Patent Expirations for SYNJARDY
Synjardy is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for SYNJARDY.
This drug has one hundred and seventy patent family members in forty-four countries.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
